MK 1484
Alternative Names: MK-1484; SP-482Latest Information Update: 07 Jun 2023
At a glance
- Originator Merck Sharp & Dohme; Sutro Biopharma
- Developer Merck Sharp & Dohme
- Class Antineoplastics; Cytokines; Immunotherapies
- Mechanism of Action Interleukin 2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 16 Jun 2022 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Combination therapy) in Netherlands, Canada (SC) (NCT05382325)
- 16 Jun 2022 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy) in Netherlands, Canada (SC) (NCT05382325)
- 16 Jun 2022 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in Israel (SC) (NCT05382325)